Ranibizumab Ranibizumab is a recombinant humanized antibody fragment (Fab) that binds VEGF. Ranibizumab binds to and inhibits all active isoforms of VEGF-A as well as their active degradation products. Two studies, MARINA (Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD) and ANCHOR (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD), demonstrated a loss of fewer than 15 ETDRS in 95% of ranibizumab-treated patients at 12 months compared with 62% of sham-treated patients and 64% of PDT-treated patients. In addition, 30%–40% of ranibizumab-treated patients experienced visual acuity improvement of 15 letters or more compared with 5% or less in the control participants (Fig 4-14, Table 4-3). Approximately 90% of ranibizumab-treated eyes lost fewer than 15 ETDRS letters at 24 months.